CCB Portal Please support MJHS Institute
Facebook Twitter YouTube LinkedIn

On-Demand Webinars:
Opioids and Other Analgesics–Package #1

Note: Institutional group rates are available upon request.

$65 for all Three Webinars (Save $10)

Select type to purchase:

Or $25 as individual Webinars

 

OPIOID THERAPY IN THE MEDICALLY ILL: SIDE EFFECT MANAGEMENT – 1.0 Credit

Speaker
Speaker Name and Title:
Russell K. Portenoy, MD
Chief Medical Officer, MJHS Hospice and Palliative Care
Executive Director, MJHS Institute for Innovation in Palliative Care
Professor of Neurology and Family and Social Medicine,
Albert Einstein College of Medicine

Funding Disclosure: No commercial funding has been accepted for the activity

Purpose:
 The purpose of this webinar is to describe the array of potential opioid side effects and toxicities in terms of their prevalence, mechanisms, and presentations, and discuss clinical strategies for prevention and management of each.

Objectives:

    1. Recognize the potential for overt and occult opioid-related toxicities
    2. Explain the evidence underlying the putative mechanisms of each side effect
    3. Apply best practices in assessing and managing opioid side effects

Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, allied health professionals, fellows, residents, and medical students.

Criteria for Successful Completion:

    1. Attendance at entire session 
    2. Submission of completed evaluation form 
    3. Successful completion of a posttest (70% for physicians, non-physicians, and nurses)

Continuing Education Credits: 1.0

Release Date: May 1, 2018

Expiration Date: June 15, 2021 (for physicians and non-physicians); February 14, 2021 (for nurses)

Continuing Education Accreditation:

Physicians: This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Medical Society of the State of New York (MSSNY) through the joint providership of MSSNY and the MJHS Institute for Innovation in Palliative Care. MSSNY is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: MJHS Institute for Innovation in Palliative Care is an approved provider of continuing nursing education by The Alabama State Nurses Association, an accredited provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Disclosures
Russell K. Portenoy, MD, Faculty and Planner, has indicated a relationship with Tabula Rasa for research support. 

No other Planning Committee Member has any disclosures.

Planning Committee Members
Lara Dhingra, PhD
Colleen Fleming-Damon, PhDc, ANP-BC, ACHPN, FT
Myra Glajchen, DSW
Helena Knotkova, PhD
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Wini Schein, BA

Select type to purchase:
 

Opioid therapy in the medically ill: principles of administration – 0.75 credit

Speaker
Speaker Name and Title:
Russell K. Portenoy, MD
Chief Medical Officer, MJHS Hospice and Palliative Care
Executive Director, MJHS Institute for Innovation in Palliative Care
Professor of Neurology and Family and Social Medicine,
Albert Einstein College of Medicine

Funding Disclosure: No commercial funding has been accepted for the activity

Purpose:
 This presentation will review best practices in the long-term use of opioid analgesics for chronic pain in populations managed by specialists in palliative care.

Objectives:

  1. Describe the clinical criteria that justify the use of opioid drugs and the factors that influence the selection of specific drugs
  2. Discuss the approach to the safe and effective use of methadone
  3. Describe the treatment of breakthrough pain
  4. Examine the dosing strategies that increase the likelihood of a favorable outcomes during opioid therapy

Target Audience:  palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, allied health professionals, fellows, residents, and medical students

Criteria for Successful Completion:

    1. Attendance at entire session 
    2. Submission of completed evaluation form 
    3. Successful completion of a posttest (70% for physicians, non-physicians, and nurses; 80% for NYS Social Workers)

Continuing Education Credits:  0.75

Release Date: May 1, 2018

Expiration Date: June 15, 2021 (for physicians and non-physicians); February 14, 2021 (for nurses)

Continuing Education Accreditation:

Physicians: This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Medical Society of the State of New York (MSSNY) through the joint providership of MSSNY and the MJHS Institute for Innovation in Palliative Care. MSSNY is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 0.75 AMA PRA Category 1 credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: MJHS Institute for Innovation in Palliative Care is an approved provider of continuing nursing education by The Alabama State Nurses Association, an accredited provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Disclosures:
Russell K. Portenoy, MD, Faculty and Planner, has indicated a relationship with Tabula Rasa for research support. 

No other Planning Committee Member has any disclosures.

Planning Committee Members
Lara Dhingra, PhD
Colleen Fleming-Damon, PhDc, ANP-BC, ACHPN, FT
Myra Glajchen, DSW
Helena Knotkova, PhD
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Wini Schein, BA

Select type to purchase:
 

This webinar is presented in collaboration with the National Hospice and Palliative Care Organization.

logos-webinar-collaboration2

What does  the palliative care specialist need to know about prescription drug abuse? – 1.0 credit

Speaker
Speaker Name and Title:
Russell K. Portenoy, MD
Chief Medical Officer, MJHS Hospice and Palliative Care
Executive Director, MJHS Institute for Innovation in Palliative Care
Professor of Neurology and Family and Social Medicine,
Albert Einstein College of Medicine

Funding Disclosure: No commercial funding has been accepted for the activity

Purpose: Patients managed by specialists in palliative care may require treatment with drugs that have the potential for abuse. To provide optimal care, palliative care specialists must be able to assess the risk of drug abuse, diagnose drug abuse behaviors, and manage potential or active abuse of both licit and illicit substances.

Objectives:

  1. Identify the patterns of drug-related behaviors that may be used to categorize drug abuse, addiction, and other outcomes
  2. Describe the process of risk assessment in the medically ill
  3. Discuss management techniques for patients with active or potential abuse behaviors

Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, allied health professionals, fellows, residents, and medical students.

Criteria for Successful Completion:

    1. Attendance at entire session
    2. Submission of completed evaluation form
    3. Successful completion of a posttest (70% for physicians, non-physicians, and nurses)

Continuing Education Credits: 1.0

Release Date: May 1, 2018

Expiration Date: May 1, 2021 

Continuing Education Accreditation:

Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Hospice and Palliative Care Organization (NHPCO) and MJHS. NHPCO is accredited by the ACCME to provide continuing medical education for physicians.

NHPCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: NHPCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NHPCO designates this enduring material for a maximum of 1.0 contact hour. Nurses should claim only the contact hours commensurate with the extent of their participation in the activity. Accredited status by ANCC refers only to continuing nursing education and does not imply endorsement of any commercial product discussed in conjunction with this activity.

Certificate of Participation for Non-Physician Healthcare Professionals: For participants* whose disciplines are other than nurse, social worker (in New York State), and physician, you may request a Certificate of Participation for Non-Physician Healthcare Professionals to submit to your accrediting bodies/licensing boards for continuing education credit. This certificate will indicate the webinar was certified for AMA PRA Category 1 Credit(s)TM. It is the responsibility of participants to submit the certificate to their accrediting bodies/licensing boards for approval. Unfortunately, NHPCO cannot guarantee its acceptance. To receive this certificate, you must complete all CE/CME requirements and indicate your desire to receive this certificate on the evaluation form.

*including finance professionals, physician assistants, social workers outside of New York State, etc.

Disclosures:
Russell K. Portenoy, MD, Faculty and Planner, has indicated a relationship with AstraZeneca Pharmaceuticals LP and Tabula Rasa for research support. 

No other Planning Committee Member has any disclosures.

Planning Committee Members
Barbara Bouton, MA, FT
Colleen Fleming-Damon, PhDc, ANP-BC, ACHPN, FT
Steven R. Gardner, MPA, PAHM
Myra Glajchen, DSW
Jennifer Kennedy, RN, MA, BSN, CHC
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Judith A. Skretny

Select type to purchase: